

(1390 REV. 5-93) US DEPT. OF COMMERCE PATENT & TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 111701
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		<b>10/019946</b>
INTERNATIONAL APPLICATION NO. PCT/FR00/02079	INTERNATIONAL FILING DATE July 19, 2000	
TITLE OF INVENTION ANALYSING DEVICE WITH BIOCHIP		
APPLICANT(S) FOR DO/EO/US Thomas GUERITAULT, Maxime ODIET, Jean-Claude PRELAZ		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>6. <input type="checkbox"/> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>7. <input checked="" type="checkbox"/> b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>8. <input type="checkbox"/> c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>9. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>10. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>11. <input type="checkbox"/> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>12. <input type="checkbox"/> b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>13. <input type="checkbox"/> c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>14. <input type="checkbox"/> d. <input type="checkbox"/> have not been made and will not be made.</p> <p>15. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>16. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>17. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p>		
<b>Items 11. to 16. below concern other document(s) or information included:</b>		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> 15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> 16. <input type="checkbox"/> Entitlement to small entity status is hereby asserted.</p> <p>17. <input type="checkbox"/> 17. <input type="checkbox"/> Other items or information:</p>		

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>10/019946</b>		INTERNATIONAL APPLICATION NO. PCT/FR00/02079	ATTORNEY'S DOCKET NUMBER 111701	
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS		PTO USE ONLY
<b>Basic National fee (37 CFR 1.492(a)(1)-(5)):</b>  Search Report has been prepared by the EPO or JPO ....\$890.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) .....\$710.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$740.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$1,040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$ 100.00				
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$890.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
<input checked="" type="checkbox"/> Claims	Number Filed	Number Extra	Rate	
Total Claims	28- 20 =	8	X \$ 18.00	\$144.00
Independent Claims	1- 3 =	0	X \$ 84.00	\$
Multiple dependent claim(s)(if applicable)		+ \$280.00		\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$1034.00		
<input type="checkbox"/> Reduction by 1/2 for filing by small entity, if applicable.		- \$		
<b>SUBTOTAL =</b>		\$1034.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 month from the earliest claimed priority date (37 CFR 1.492(f)).		\$		
<b>TOTAL NATIONAL FEE =</b>		\$1034.00		
		Amount to be refunded		\$
		Charged		\$
a. <input checked="" type="checkbox"/> Check No. <u>126630</u> in the amount of <u>\$1034.00</u> to cover the above fees is enclosed.				
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.				
c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. <u>15-0461</u> . A duplicate copy of this sheet is enclosed.				
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>				
SEND ALL CORRESPONDENCE TO: OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320				
 NAME: William P. Berridge REGISTRATION NUMBER: 30,024				
Date: <u>January 7, 2002</u> NAME: Thomas J. Pardini REGISTRATION NUMBER: 30,411				

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>10/019946</b>	INTERNATIONAL APPLICATION NO. <b>PCT/FR00/02079</b>	ATTORNEY'S DOCKET NUMBER <b>111701</b>	
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS	PTO USE ONLY
<b>Basic National fee (37 CFR 1.492(a)(1)-(5)):</b>  Search Report has been prepared by the EPO or JPO ....\$890.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) .....\$710.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$740.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$1,040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$ 100.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
Claims	Number Filed	Number Extra	Rate
Total Claims	28- 20 =	8	X \$ 18.00 \$144.00
Independent Claims	1- 3 =	0	X \$ 84.00 \$
Multiple dependent claim(s)(if applicable)		+ \$280.00 \$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$1034.00	
Reduction by 1/2 for filing by small entity, if applicable.		- \$	
<b>SUBTOTAL =</b>		\$1034.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 month from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
<b>TOTAL NATIONAL FEE =</b>		\$1034.00	
		Amount to be refunded	\$
		Charged	\$
a. <input checked="" type="checkbox"/> Check No. <u>126630</u> in the amount of <u>\$1034.00</u> to cover the above fees is enclosed.			
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.			
c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. <u>15-0461</u> . A duplicate copy of this sheet is enclosed.			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>			
SEND ALL CORRESPONDENCE TO:			
OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320			
Date: <u>January 7, 2002</u>		 NAME: William P. Berridge REGISTRATION NUMBER: 30,024	
		NAME: Thomas J. Pardini REGISTRATION NUMBER: 30,411	

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Thomas GUERITAULT, Maxime ODIET, Jean-Claude  
PRELAZ

Application No.: New U.S. National Stage of  
PCT/FR00/02079

Filed: January 7, 2002 Docket No.: 111701

For: ANALYSING DEVICE WITH BIOCHIP

**PRELIMINARY AMENDMENT**

Director of the U.S. Patent and Trademark Office  
Washington, D. C. 20231

Sir:

Prior to initial examination, and after entry of the Annexes to the IPER, please amend the above-identified application as follows:

**IN THE ABSTRACT:**

Please add the Abstract as attached hereto.

**IN THE CLAIMS:**

Please replace claims 4,6,10-12,14,15,17-19,21,24,27 and 28 as follows:

4. (Amended) The analytical device as claimed in claim 1, characterized in that the attachment means completely exposes the active face (3).

6. (Amended) The analytical device as claimed in claim 1, characterized in that the attachment means (5) is an adhesive.

10. (Amended) The analytical device as claimed in claim 7, characterized in that the interstice between the border of the window (81) and the transverse strip (7) of the biochip is between 2 mm and 0.05 mm, advantageously between 0.5 mm and 0.05 mm, and preferentially between 0.2 mm and 0.1 mm.

11. (Amended) The analytical device as claimed in claim 1, characterized in that the attachment means extends along the entire transverse strip (7) of the biochip.

12. (Amended) The analytical device as claimed in claim 1, characterized in that the attachment means (5) connects two opposite zones of the transverse strip (7), to the container (8).

14. (Amended) The analytical device as claimed in claim 1, characterized in that the support (9) of the biochip (2) is a parallelepiped, the active (3) and opposite (6) faces of which are each rectangular or square.

15. (Amended) The analytical device as claimed in claim 1, characterized in that the reaction compartment (10) is arranged so as to bring a liquid medium, subjected to the analysis, and the active surface (31) of the biochip into contact.

17. (Amended) The analytical device as claimed in claim 1, characterized in that the active surface (31) of the biochip has a surface area of less than 100 mm<sup>2</sup>, advantageously less than 65 mm<sup>2</sup>, and preferentially less than 30 mm<sup>2</sup>.

18. (Amended) The analytical device as claimed in claim 1, characterized in that the active surface (31) of the biochip represents at least 75% of the surface area of the active face (3).

19. (Amended) The analytical device as claimed in claim 1, characterized in that the ligands are nucleic acids.

21. (Amended) The analytical device as claimed in claim 1, characterized in that the attachment means (5) comprises means which are flexible (12) at the level of the window (81) of the container (8), and exert a pressure on the transverse strip (7) of the biochip (2) so as to facilitate the positioning and/or the maintaining in position of said biochip.

24. (Amended) A process for attaching a biochip to a container, for producing an analytical device as claimed in claim 1, characterized in that the biochip (2) is maintained opposite the container (8), in that a liquid adhesive seal is distributed between the transverse

strip (7) of the biochip and the container (8), and in that the adhesive (5) is cured by ultraviolet radiation.

27. (Amended) The attachment process as claimed in claim 24, characterized in that ultraviolet radiation is applied to the adhesive seal on at least one of the faces of the analytical device.


28. (Amended) The attachment process as claimed in claim 24, characterized in that a mask is positioned between the biochip and the ultraviolet radiation in order to protect the ligands in the active surface (31).

REMARKS

Claims 1 - 28 are pending. By this Preliminary Amendment, an abstract is added and claims 4,6,10-12,14,15,17-19,21,24,27 and 28 are amended to remove multiple dependencies. Prompt and favorable examination on the merits is respectfully requested.

The attached Appendix includes marked-up copies of each rewritten claim (37 C.F.R. 1.121(c)(1)(ii)).

Respectfully submitted,

  
William P. Berridge  
Registration No. 30,024

Thomas J. Pardini  
Registration No. 30,411

WPB:TJP/mlb  
Attached: Abstract  
Appendix  
Date: January 7, 2002

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

DEPOSIT ACCOUNT USE  
AUTHORIZATION  
Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461

## APPENDIX

## Changes to Claims:

The following are marked-up versions of the amended claims:

4. (Amended) The analytical device as claimed in claim 1-~~or 2~~, characterized in that the attachment means completely exposes the active face (3).

6. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 5~~, characterized in that the attachment means (5) is an adhesive.

10. (Amended) The analytical device as claimed in ~~claim 7any one of claims 7 to 9~~, characterized in that the interstice between the border of the window (81) and the transverse strip (7) of the biochip is between 2 mm and 0.05 mm, advantageously between 0.5 mm and 0.05 mm, and preferentially between 0.2 mm and 0.1 mm.

11. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 10~~, characterized in that the attachment means extends along the entire transverse strip (7) of the biochip.

12. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 11~~, characterized in that the attachment means (5) connects two opposite zones of the transverse strip (7), to the container (8).

14. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 13~~, characterized in that the support (9) of the biochip (2) is a parallelepiped, the active (3) and opposite (6) faces of which are each rectangular or square.

15. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 14~~, characterized in that the reaction compartment (10) is arranged so as to bring a liquid medium, subjected to the analysis, and the active surface (31) of the biochip into contact.

17. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 16~~, characterized in that the active surface (31) of the biochip has a surface area of less than 100 mm<sup>2</sup>, advantageously less than 65 mm<sup>2</sup>, and preferentially less than 30 mm<sup>2</sup>.

18. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 16~~, characterized in that the active surface (31) of the biochip represents at least 75% of the surface area of the active face (3).

19. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 18~~, characterized in that the ligands are nucleic acids.

21. (Amended) The analytical device as claimed in ~~claim 1any one of claims 1 to 20~~, characterized in that the attachment means (5) comprises means which are flexible (12) at the level of the window (81) of the container (8), and exert a pressure on the transverse strip (7) of the biochip (2) so as to facilitate the positioning and/or the maintaining in position of said biochip.

24. (Amended) A process for attaching a biochip to a container, for producing an analytical device as claimed in ~~claim 1any one of claims 1 to 23~~, characterized in that the biochip (2) is maintained opposite the container (8), in that a liquid adhesive seal is distributed between the transverse strip (7) of the biochip and the container (8), and in that the adhesive (5) is cured by ultraviolet radiation.

27. (Amended) The attachment process as claimed in ~~claim 24any one of claims 24 to 26~~, characterized in that ultraviolet radiation is applied to the adhesive seal on at least one of the faces of the analytical device.

28. (Amended) The attachment process as claimed in ~~claim 24any one of claims 24 to 27~~, characterized in that a mask is positioned between the biochip and the ultraviolet radiation in order to protect the ligands in the active surface (31).

4/Prb

WO 01/05504

PCT/FR00/02079

### Analytical device with biochip

The present invention relates to a device for analyzing at least one analyte, comprising a container 5 and a biochip, the latter being attached to the container by a suitable means of attachment.

The term "biochip" is intended to mean, and with reference to Figure 1, any component comprising, in a way known per se, a support 9, in particular 10 polyhedral in shape, for example parallelepipedal in shape. This support 9 comprises, firstly, an active face 3 comprising an active surface 31, onto which are distributed and attached a plurality of ligands 4 used for the analysis and, optionally, depending on the 15 detection method used, a peripheral zone 32 free of ligands, secondly, at least one face 6 opposite the active face, for example parallel to the active face, and a transverse and peripheral strip 7, or edge, connecting the active 3 and opposite 6 faces, 20 comprising, for example, several sides 71 to 74 in the case of a parallelepipedal shape.

Advantageously, the surface area of the active surface is less than 100 mm<sup>2</sup>, for example less than 25 65 mm<sup>2</sup>, and preferentially less than 30 mm<sup>2</sup>. The thickness of support, for example the width of the transverse strip 7, is less than 5 mm, advantageously less than 1 mm. In certain cases, the biochip support is in the shape of a cylindrical disk, in which case, the transverse strip has no edge.

30 Preferentially, the active surface represents at least 75% of the surface area of the active face.

The ligands may be attached in various ways, in particular by adsorption or covalence, such as for example in situ synthesis by photolithography 35 techniques, or by a piezoelectric system, by capillary deposit of preformed ligands. By way of illustration, examples of these biochips are given in the

publications by G. Ramsay, *Nature Biotechnology*, 16, p. 40-44, 1998; F. Ginot, *Human Mutation*, 10, p. 1-10, 1997; J. Cheng et al, *Molecular diagnosis* 1(3), p. 183-200, 1996; T. Livache et al, *Nucleic Acids Research*, 5 22(15), p. 2915-2921, 1994; J. Cheng et al, *Nature Biotechnology*, 16, p. 541-546, 1998, or in patents US 4981783 (Augenlicht), US 5700637 (Southern), US 5445934 (Fodor), US 5744305 (Fodor), US 5807522 (Brown).

The state of the art consists of the document 10 WO 95/33846, which describes a consumable for biological analysis, in which a biochip is attached to a plastic support. This parallelepipedal-shaped biochip comprises, on its active face, a large number, generally several thousands to several hundreds of 15 thousands, of oligonucleotides placed at predetermined locations. Several means for attaching the biochip are described, both by adhesive bonding and by sealing. However, in all cases, part of the active face of the biochip, where the oligonucleotides are located, is 20 used for the attachment to the plastic. In this case, the area on the active face used for attaching the biochip to the consumable is not available for oligonucleotides to be grafted onto it.

There are two constraints for the industrial 25 application of these biochips. Firstly, the desire to reduce production costs for these biochips involves a decrease in the size of the latter, with, as an indirect consequence, a decrease in the size of the consumable, which decreases the costs of the device 30 accordingly. Secondly, the desire to carry out several simultaneous analyses (such as detecting a panel of pathogenic agents in a biological sample, or detecting the effect of a molecule on the expression of a multitude of messenger RNAs in order to identify the 35 metabolic pathway on which this molecule acts) with the same biochip leads to an increase in the number of ligands on the surface of the biochip. Thus, industrial logic deems that a maximum number of ligands be placed on a minimum surface area.

The technique described in application WO 95/33846 therefore has the major drawback of using part of the active face of the biochip for attaching it to a consumable, which is not compatible with the 5 industrial constraints described above.

In addition, it is important that the optical detection should not be affected by the means of attachment.

The present invention solves the problem thus 10 posed, by providing, in general, a single means for attaching the biochip which connects, on one side, the transverse strip, or edge, of the support of said biochip, virtually excluding any other part, face or surface of said biochip, and, on the other side, the 15 container, this being on both sides of the active face of the biochip; and this attachment means completely exposes moreover the peripheral zone of the active face of the biochip, i.e. it neither obstructs nor masks, at least in part, said active face.

20 The term "virtually" is intended to mean that the attachment means exposes at least 95% of the entire active face, advantageously at least 97%, and preferentially at least 99%.

According to the present invention, two 25 scenarios should be envisaged, depending on whether, as a function of the method for detecting the ligands, the active surface merges with the complete surface of the active face, or whether a peripheral zone, free of ligands, surrounds the active surface and extends in 30 width between said active surface and the edge of the active face.

In the first case, the attachment means exposes virtually entirely, if not completely, the active surface.

35 In the second case, the attachment means also exposes, virtually entirely, if not completely, the peripheral zone of the active face.

A certain number of terms used in the present invention are explained below.

The term "analytical device" is intended to mean any apparatus which allows the analysis of one or more different liquid or gaseous samples, in which the intention is to identify and/or quantify one or more analytes according to any simple or complex analytical process involving one or more different reagents, depending on the chemical, physical or biological nature of the analyte(s) sought. The technical principles defined hereinafter are not limited to a particular analyte, the only condition required being that the analyte is distributed in the sample to be analyzed, in suspension or in solution. In particular, the analytical process used may be carried out in a homogeneous, heterogeneous or mixed form. One example of application of the analytical techniques relates to immunoassays, whatever their format, by direct analysis or by competition. Another example of application relates to the detection and/or quantification of nucleic acids, comprising all the operations necessary for this detection and/or this quantification using any sample containing the target nucleic acids. Among these various operations, mention may be made of lysis, fluidization, concentration, steps for enzymatically amplifying the nucleic acids, and detection steps which incorporate a hybridization step. Patent application WO 97/02357, the content of the description of which is incorporated into the present application, explains various steps required in the case of nucleic acid analysis.

The term "ligand" is intended to mean any biological or chemical species capable of reacting specifically with a receptor present on the analyte. By way of example of a ligand, mention may be made of an antigen, an antigen fragment, a peptide, an antibody, an antibody fragment, a hapten, a nucleic acid, a nucleic acid fragment, a polynucleotide, a hormone, a vitamin, a sugar, a polysaccharide, a chelator, a drug, a cofactor and a chemical molecule capable of binding by covalence or by adsorption. Advantageously, the

ligands attached to the biochip are nucleic acids, and preferentially oligonucleotides, and are attached to the biochip by covalent coupling. In a preferential embodiment, at least 400 different oligonucleotide sequences, and preferentially at least 1 000, are attached per cm<sup>2</sup> of the solid support of the biochip.

The solid support should be suitable for the attachment of the ligands. Natural or synthetic materials, which may or may not be chemically modified, may be used as a solid support, in particular polymers such as polyvinyl chlorides, polyethylenes, polystyrenes, polyacrylates or polyamides, or copolymers based on monomers of the styrene type, unsaturated carboxylic acid esters, vinylidene chloride, dienes or compounds having nitrile functions (such as acrylonitrile); inorganic materials such as silica, quartz, glass, ceramics; metal derivatives. In particular, the solid support is made of nonporous material. In a particular embodiment, the solid support is made of a material which is transparent to light, and in particular glass or derivatives.

The "container" is defined as the piece or set of pieces allowing the analysis to be carried out, and to which the biochip is attached, the container and said biochip delimiting together at least one reaction compartment. In particular, this container allows the introduction of a fluid, and in particular of the liquid in which the analyte(s) to be analyzed is (are) located, and makes it possible to delimit at least one reaction compartment so as to promote the reaction between the ligands and the analyte(s).

According to a variant of the invention, the attachment means ensures that the reaction compartment is leaktight with respect to the outside.

Preferentially, the active surface faces the inside of the container so as to allow contact between the liquid medium, the analysis of whose content is desired, and the ligands attached to this active

surface, and the opposite face faces the outside of the container.

By way of example, this container is a single-use consumable as described in patent applications 5 WO 95/33846, WO 97/02357 and WO 97/27324. However, it may also be reused. The content of the description of these abovementioned patent applications is considered to be incorporated into the description of the present invention. In a preferential embodiment according to 10 the invention, the container is made of a plastic material, such as polypropylene or polystyrene, and it is obtained by molding. According to a variant of the invention, surface treatment may be carried out on the container, especially if the container is made of 15 polyolefin, and in particular if the container is made of polypropylene, in order to increase the adhesion of the adhesive on the container. This surface treatment may be a Corona treatment, flame brushing, cleaning of the surfaces, such as degreasing, or chemical etching 20 of the surface.

In order to attach the biochip to a container, it is necessary to provide the container with a component capable of receiving the biochip. This reception zone is defined as being the window of the 25 container. In particular, this window has a transverse profile substantially identical to that of the support of the biochip, but is slightly larger in size. The term "slightly larger" is intended to mean an interstice between the transverse strip of the biochip 30 and the border of the window of the container, of between 2 mm and 0.05 mm, advantageously of between 0.5 mm and 0.05 mm, and preferentially of between 0.2 mm and 0.1 mm.

This interstice in particular has an even value 35 along the transverse border of the support of the biochip, which is relatively low, either to allow the adhesive to be kept in the liquid state, by capillarity, for as long as it has not been cured, or

to avoid the adhesive running if it is sufficiently viscous.

The term "attachment" is intended to mean any solution or means allowing any permanent bonding 5 between the biochip and the container, respecting the abovementioned definition. By way of example, mention may be made of laser soldering, ultrasound soldering, microplasma soldering, induction soldering, high-frequency soldering, anodic bonding, adhesive bonding, 10 molecular adhesion, hot-crimping, mechanical blocking by clipping, fastening by a stop system, by flexible, i.e. deformable, attachment, such as with a rubber seal.

Advantageously, the attachment is carried out 15 by adhesive bonding, for example with multicomponent adhesives, for example, such as a dental adhesive, an adhesive based on a polymer dissolved in a solvent (polystyrene dissolved in xylene for example), polyurethane adhesives, epoxy adhesives, instant 20 adhesives such as cyanoacrylate adhesives, UV adhesives, i.e. adhesives which cure under the action of ultraviolet radiation. Adhesives of this type are sold by the company DYMAX (Torrington CT, USA) under the reference 128-M or the reference 1-20-270 or 1-20- 25 280, or by the company EPOTECNY (Vélizy, France) under the reference NOA 63, NOA 68, NOA 72 or NEA 121, or by the company LOCTITE (Dublin, Ireland) under the reference 3011, 3301, 3311, 3104 or 3105. Preferentially, the attachment is carried out with an 30 adhesive which can be cured by ultraviolet radiation, such as the adhesive Dymax 1-20-280.

In a particular embodiment of the invention, the attachment means extends along the entire transverse strip of the biochip. According to a variant 35 of the invention, and in particular when the biochip support is a rectangle-based or square-based parallelepiped, and when the attachment is performed by adhesive bonding, the adhesive seal covers the four sides and the four right angles. In a preferential

embodiment of the invention in which the attachment is performed by adhesive bonding, the container has a particular structure at the level of the zone of attachment between the transverse strip of the biochip  
5 and the window of the container, such as for example a beveled shape so as to allow a possible excess of adhesive to position itself on the container part. A ledge may also be present on the container in order to eliminate this possible excess of adhesive, as will be  
10 explained on the figures. This means makes it possible to store a surplus of adhesive without it overflowing onto the peripheral zone of the biochip.

Still in this embodiment by adhesive bonding, and with the aim of improving the mechanical resistance  
15 of the adhesive seal, a concavity may be made on all or part of the surround of the window of the container, such as for example a groove or a channel. The adhesive, by curing inside at least part of the concavity, improves the attachment between the  
20 container and the biochip.

In another particular embodiment of the invention, the attachment means connects two opposite zones of the transverse strip of the biochip. In this case, along the transverse strip, the attachment means  
25 is discontinuous between the biochip and the container.

According to another variant, the attachment means connects four zones of the transverse strip of the biochip, the four zones being distributed substantially symmetrically so as to increase the  
30 rigidity, and therefore the mechanical strength, of the analytical device.

According to another variant of the invention, the attachment means comprises means which are flexible at the level of the window of the container, and exert  
35 a pressure on the transverse strip of the biochip so as to facilitate the positioning of said biochip. For example, a window with a particular geometry is produced on the container when it is injected with a plastic material. These flexible means are designed to

receive the biochip and to maintain it in place. These means should be sufficiently flexible to allow the insertion of the biochip, with moderate force, but sufficiently rigid to allow good reproducibility of 5 insertion without, however, being brittle.

The function of these means is to attach the biochip or to maintain it in place, before carrying out the definitive attachment. By way of example, these means maintain the biochip in place by virtue of the 10 pressure exerted on the four sides of the square-based parallelepipedal shape, long enough to place a line of adhesive of the UV type. Once the curing has taken place, the attachment of the biochip to the container is complete.

15 According to a variant of the invention, the flexible means consist of two interdependent components, namely a first component, or intermediate component, inclined relative to the opposite face of the biochip, and a second component, or end component, 20 perpendicular to said opposite face, and which presses the transverse strip of the biochip.

According to another variant of the invention, the flexible means comprise claws, the cross section of which is substantially triangular. These claws exert a 25 pressure on the transverse strip, or edge, of the biochip.

According to a variant of the invention, the biochip support consists of a material which is transparent to light, such as for example glass or 30 glass derivatives. This variant is particularly advantageous for optically reading the analytical reaction, such as for example reading fluorescence through the glass.

With the attachment solution of the present 35 invention, the active surface of the biochip, where the ligands are attached, may start as close as possible to the border of the support. The wall of the container may block some of the light emitted during the revelation. This limitation has two consequences: it

locally decreases the spatial resolution of the biochip and locally decreases the collective intensity, so locally decreases the sensitivity of the detection dynamics. There is therefore a margin  $m$  which must be  
5 respected, belonging to the peripheral zone 32, which is the distance between the edge of the biochip and the active surface where the ligands are grafted. The calculation of this margin is related to the numerical aperture of the optic, and to the thickness and index  
10 of the glass of the biochip. If the numerical aperture of the optic is denoted  $NA$ , the refractive index of the glass is denoted  $n$  and the thickness of the glass is denoted  $e$ , the optical margin  $m$  is equal to  $e \cdot tg [\arcsin (NA/n)]$ . By way of example, for a glass  
15 thickness of 0.7 mm and an index of 1.46, the margin  $m$  varies between 255 and 548  $\mu m$ , for optics with a numerical aperture of between 0.5 and 9.

In the most unfavorable case, for a biochip with a square active face having a surface area of  
20 25  $mm^2$ , the surface area of the peripheral zone 31 may be decreased to 9.9% of the surface area of the active face 3; whereas, prior to the invention, with a conventional attachment means, this same surface area may represent up to 80% of the surface area of the  
25 active face 3.

The ligands 4 may be distributed over at least 75% of the surface area of the active face of the biochip, and advantageously at predetermined positions. It is clear that this margin, in the case of the  
30 present invention, is minimal, since the attachment means according to the present invention virtually completely exposes the peripheral zone, both on the active face and on the opposite face.

The invention also relates to a process for  
35 attaching a biochip to a container, so as to produce an analytical device, characterized in that the biochip is maintained opposite the container, in that a liquid adhesive seal is distributed between the transverse

strip of the biochip and the container, and in that the adhesive is cured by ultraviolet radiation.

In a particular embodiment of the invention, the biochip is arranged relative to the container so as 5 to place the transverse strip of the biochip opposite the frame of the window of the container and allow the attachment.

Advantageously, two positioning means are available, one for the biochip and one for the 10 container.

These positioning means may consist of a block, for example metal block on which the container rests. In a particular embodiment of the invention, a means for maintaining the container and/or the biochip in 15 place consists in applying a vacuum using at least one orifice placed on the block. A means for positioning the biochip may consist of a support, for example a cylindrical support, on which the biochip rests, and which has at least one orifice opening out onto the 20 surface in contact with the biochip, in order to apply a vacuum to maintain the latter. The movements of these positioning means may be controlled by a robot along the x, y and z axes. A positioning precision of the order of  $\pm 0.2$  mm may be easily attained, insofar as 25 the positioning references can be located in automatic mode, either by artificial vision or mechanically. In the case of optical reading, such as for example reading by fluorescence with a CCD camera or a laser, the flatness of the active surface is important, such 30 as for example with a tolerance of 50 micrometers along the diagonal so as not to distort the focusing of the optical system. The present invention solves this problem, in particular in the case of the attachment by an adhesive seal, since said seal makes it possible to 35 compensate or absorb the imperfections on the surface, both on the transverse strip, or edge, of the biochip and on the frame of the window of the container. In an embodiment in which the support of the biochip is made of glass or glass derivative, and in which said biochip

DEPOSITA BREVETTO

is obtained from a sheet which is cut up as described in patent WO 95/33846, or by other techniques, such as the diamond saw, waterjet or laser cutting, the method of attachment by placing an adhesive seal between the 5 biochip and the window of the container is particularly suitable. Similarly, this technique makes it possible to decrease the constraints of surface finish on the mold, when the container is obtained by molding an engineering plastic material.

10 The ultraviolet radiation is applied to the adhesive seal by illuminating at least one of the faces of the analytical device. In a first embodiment, when the container is made of a single component, such as for example a consumable of the cart type as described 15 in the Applicant's patent application FR 2749663, the container is provided with a window for putting the biochip in place. After the biochip has been put in place opposite the window of the container, and the adhesive seal has been deposited, the curing is carried 20 out in a step of 10 to 40 seconds.

In a second embodiment, in which the container is made of two components, the adhesive seal is cured in two steps. After the container and the biochip have been put in place using the positioning means, a first 25 step consists in pre-curing the spot of adhesive by UV irradiation for a short time, between 2 and 30 seconds, and advantageously between 5 and 15 seconds. In a second step, the adhesive is cured by UV irradiation from the other side, over a period of time of between 5 30 and 40 seconds, and advantageously between 15 and 30 seconds. These times vary depending on the nature of the adhesive and on the power of the irradiation lamp, and are determined by those skilled in the art. A short curing time should be sought in order to increase the 35 manufacturing process rate.

A mask is positioned between the biochip and the ultraviolet radiation in order to protect the ligands on the active face against the effect of the ultraviolet radiation, which may degrade biological or

chemical molecules. In a variant of the invention, the means for positioning the biochip acts as the mask. In another variant of the invention, a finger which is adjustable in height makes it possible to protect the 5 active face of the biochip.

The figures and examples below are given by way of explanatory example and are in no way limiting in nature. They will make it possible to understand the invention more clearly. In the interests of clarity of 10 the drawing, the various elements of the drawings are not represented to scale.

In the attached drawing:

- as mentioned above and already described, 15 Figure 1 represents, diagrammatically and in perspective, a biochip as considered by the present invention;

- Figure 2 diagrammatically represents a partial sectional view of an analytical device according to an embodiment of the present invention;

20 - Figure 3A diagrammatically represents a sectional view of the zone of attachment of a biochip to a container, according to a particular embodiment of the present invention;

25 - Figure 3B represents a preferential attachment means according to the invention, in which a means 14 for eliminating a surplus of adhesive is represented. This means, as in Figure 3A, has a beveled shape at the level of the window 81 of the container and forms a 45° angle. Other angles may be used. Unlike 30 Figure 3A, the ledge 141 at the end of the bevel is in height, for example between 0.05 and 0.1 mm for a biochip thickness of 0.7 mm. The interstice between the peripheral part of the biochip and the ledge 141 is decreased such that the adhesive cannot slide into the 35 interstice as represented on Figure 3B. The beveled shape also makes it possible to facilitate the positioning of the needle between the container and the biochip and, in addition, makes it possible to avoid the adhesive overflowing onto the upper surface of the

biochip 2. The ledge 141, combined with the interstice and the viscosity of the adhesive, makes it possible to avoid the adhesive flowing into the interstice and therefore the adhesive overflowing onto the active face 5 3 of the biochip. This attachment means therefore allows optical reading over the entire active face with as large an active surface as possible;

10 - Figure 4 diagrammatically represents a sectional view of the zone of attachment of a biochip to a container, according to another particular embodiment of the present invention;

15 - Figure 5 represents a sectional view of the zone of attachment of a biochip to a container, with flexible means made of two components;

20 - Figure 6 represents a sectional view of the zone of attachment of a biochip to a container, with flexible means in the form of a claw;

25 - Figure 7 represents a view according to F from above of the claw represented in Figure 6;

30 - Figure 8 represents a part of the window of the container, with a means for storing the surplus of adhesive in the form of a groove;

35 - Figures 9 to 11 represent, respectively, a first step, a second step and a third step of the process for attaching the biochip to a container, according to a particular embodiment of the present invention;

40 - Figure 12 diagrammatically represents a test rig for the adhesive bonding;

45 - Figure 13 diagrammatically represents the test rig for the mechanical resistance tests and tests for leaktightness.

50 Figure 2 shows a partial sectional view of an analytical device 1 in which a biochip 2 is attached to a container 8, via an attachment means 5. This attachment means, represented on Figure 2 by an adhesive seal, encroaches onto neither the active face 3, on which the ligands are present, nor the opposite face 6. To do this, the adhesive seal is present

between the transverse strip 7, or edge, of the biochip or, more precisely, of its support, and the frame of the window 81 of the container 8. In this embodiment, the active surface 31 of the biochip is facing the 5 inside of the container, and the opposite face is facing the outside. A liquid, containing analytes, and not represented on the figure, may thus interact with the ligands 4 in the reaction compartment 10. The adhesive seal ensures that the compartment 10 is 10 leaktight with respect to the outside, on this part of the container. The analytical device is represented diagrammatically, but it is clearly understood that those skilled in the art may vary the various elements of said device depending on the analysis or analyses to 15 be carried out, without, however, straying from the context of the invention. Among these nonrepresented elements, mention may be made of: the system for the introduction and/or for the exit of the sample, and also of possible reagents required for the analysis; a 20 set of channels to direct the liquid; systems of valves which make it possible to control the movement of the liquid sample introduced; means for displacing liquid; means for controlling the temperature; reagent storage zones. Many descriptions of valves exist in the prior 25 art, and in particular the valves described in the patent application filed by the Applicant, dated September 8, 1998, under the filing number FR-98/11383. The systems for displacing fluid, such as pumping systems, may be incorporated on the inside or on the 30 outside of the device, such as for example diaphragm pumps (US 5277556), piezoelectric peristaltic pumps (US 5126022), systems for transport with ferrofluids, or electrohydrodynamic pumps (Richter et al., Sensors and Actuators, 29, p. 159-165, 1991).

35 Of course, a channel or several channels make(s) it possible to lead the liquid into the reaction compartment 10. These combined channels may be integrated into said analytical device 1, and allow the liquid to be sent toward other zones of the container

or toward other containers, where other treatments and/or reactions may be performed. Similarly, one or more biochips 2 may be attached to the same container 8 in the case of multiple analysis.

5 Figures 3A, 3B and 4 present a sectional view of the attachment of the biochip 3 in the window 81 of the container 2, according to a particular and preferential method of attachment according to the invention, in which a means 14 for eliminating a  
10 possible surplus of adhesive is represented. In Figures 3A and 3B, this means 14 has a beveled shape at the level of the window 81 of the container. The angle represented is 45°, but other angles may be used, as long as the adhesive can travel back along this slope.  
15 Figure 4 represents a variant of the attachment method represented in Figure 2, in which a ledge is added between the biochip and the beveled shape.

On these diagrams, the frame of the window 81 has an edge parallel to the transverse strip 7 of the  
20 biochip 6. This configuration has two advantages: improvement of the mechanical resistance of the window and increase in the surface area of contact for the adhesive on the container 8, which improves the attachment.

25 Figures 5 and 6 represent another embodiment of the present invention, with sectional views of the zone of attachment of the biochip 2 to the container 8, with the addition of flexible means 12 which promote the maintaining in position of the biochip. On Figure 5,  
30 these flexible means 12 are made of two components. A first component 121 is inclined relative to the opposite face 6 of the biochip, and an end component 122 is substantially perpendicular to said opposite face and, therefore, in the case of the diagram,  
35 parallel to the transverse strip 7 of the biochip. This end component pushes against a side of the biochip so as to facilitate maintaining the biochip in place or positioning it. On Figure 5, an attachment means represented by an adhesive seal 35 ensures the

leaktightness of the attachment, but it is possible to maintain the biochip in place solely by the pressure of the flexible means 12. In order to maintain the biochip 2 in place, it is clearly understood that the pressure forces applied onto the biochip by these means 12 cancel one another out, and those skilled in the art will define the number and positioning of these means on the window 81 of the container in order to respect this constraint. In the case of a biochip with a square parallelepipedal shape, one or two means 12 opposite one another on the two sides, respectively, are suitable.

The angle between the first inclined component 121 of the flexible means 12 and the opposite face 6 of the biochip has two functions: to allow the biochip 2 to be inserted vertically so as to place it facing the container 8 without breaking said flexible means, and to allow the elimination of the surplus of adhesive, as for the beveled component described above with reference to figures 3 and 4. The flexible means are produced, for example, by injection with plastic polymers such as polypropylene.

On figure 6, the flexible means 12 is a beveled claw, the cross section of which is substantially triangular, the tip of the claw pressing a side of the biochip. The beveled component has the same advantages as those described above for the flexible means 12. Figure 7 shows a view of the container/biochip junction, demonstrating the triangular cross section of this claw.

Other forms of flexible means 12 exist.

Figure 8 shows a partial view, in perspective, of the window of the container 13, in which a concavity 15, in the form of a groove, is present in the frame of the window 81, so as to make it possible to improve the attachment of the adhesive to the container 8. The biochip, not represented on the drawing, is a square biochip, and the drawing represents one side of the window 81. On the drawing, this groove is present on

the entire portion of window represented, but it is possible to have this groove on only part of the surround of said window. The beveled form of the window is represented in this embodiment, but is not necessary 5 since the groove 15 can eliminate the excess of adhesive.

Figure 9 is a diagrammatic representation of the first step of the attachment process according to an embodiment in which the container 8 and the glass 10 biochip 2 are put in place using the positioning means 180 and 18, respectively. A mask 19 is located between the positioning means 18 and the biochip 3.

On figure 10, an adhesive distributor 20 equipped with its needle 21 delivers the amount of 15 adhesive over the entire surround located between the window 81 of the container 8 and the transverse strip 7 of the biochip 2, and pre-curing is carried out by UV irradiation via the ring light 17 located below the biochip.

20 Figure 11 represents the last step of the attachment process, during which the curing is finished by UV irradiation from above, using another ring light 17, itself also equipped with a mask 19 to protect the active face of the biochip.

25

Example 1: Attachment of a biochip to a container by adhesive bonding

30 A test rig was prepared, making it possible to deposit an adhesive seal between the biochip 2 and the container 8. This test rig is represented diagrammatically on figure 12.

35 A lower base 43 is equipped with a ring light 44, the height of which can be adjusted manually, placed around the support 46 for the biochip 2. The ring light 44 is protected by an interchangeable quartz lens, when the adhesive would run onto the ring during the tests. The biochip 2 is maintained, by vacuum, on its support 46, the height of which can also be adjusted manually. This base is designed to also

receive a consumable or single-use element which plays the role of the container 8, and which is positioned with two reference pins 41. An interchangeable heat mask 42 makes it possible to illuminate the adhesive seal 5 and to protect the biochip 2 depending on its aperture. An upper block 48 takes the form of a removable lid. It is equipped with a ring light 49 which allows the adhesive seal 5 to be illuminated from above the container 8. The ring light 49 is identical 5 to that 44 of the base 43. An upper finger 47 makes it possible to protect the active surface of the biochip, without contact between this finger and the biochip 2. The height of this finger can be adjusted manually. The element 8 can be adjusted in the x, y directions over 10 the surface 50, using the reference pins 41. The UV light originates from two light sources of the SUPERLITE SUV-DC-P type from the company Lumatec, each having a power of 200 W. An adhesive distributor, like 15 that described with reference to figure 10, of the internal pressure type, is mounted along the z axis of an AUTOPLACE 420 robot from the company Sysmec (Neuchatel, Switzerland), via an attachment which makes 20 it possible to incline the needle. The robot is controlled by an AUTOPLACE control organ from the company Sysmec, and the parameters of the assembly 25 and adhesive bonding process are controlled by a microcomputer. The needle for distributing the adhesive is a Teflon® needle. The adhesive is metered according to the pressure/time principle, i.e. a given pressure 30 is applied for a given time.

The consumable element 8 is produced by machining using a plastic material made of polystyrene, with a window 81 which is variable in size. The window of the container has a square cross section which is 35 5.717 mm ± 0.05 or 5.577 mm ± 0.05, or 5.437 mm ± 0.05 in size.

The biochip 2 has, as a support, a glass square which is 5.37 mm ± 0.18 in size and 0.7 mm thick.

Four adhesives, in particular based on acrylates, for example urethane acrylates, were tested: the Dymax 128M, Dymax 1-20280, Loctite 3104 and Loctite 3105 adhesives. The tests carried out show that a value 5 of 0.8 bar ( $8 \times 10^4$  Pa) as the pressure for metering the adhesive makes it possible to correctly control this metering. The needle is used in the vertical position, since this position makes it possible to have a minimum distance between the tip of the needle and the 10 biochip/container interface. The amount of adhesive used for the various tests is a few  $\text{mm}^3$  per adhesive seal.

In a first series of tests, the adhesive is pre-cured from below for 10 seconds, and then cured 15 from above for 20 seconds.

In a second series of tests, the adhesive is pre-cured from below for 5 seconds, and then cured from above for 20 seconds.

In a third series of tests, the adhesive is 20 pre-cured from below for 10 seconds, and cured from above for 2 minutes.

All the tests show, by analysis under a microscope, that the adhesive seal 5 has a very good visual appearance, i.e. its contour around the biochip 25 is characterized by a very homogeneous geometry and there is no adhesive either on the active surface of the biochip or on the opposite face.

Even with the shortest curing time, which corresponds to the second series of tests, it is 30 possible to transfer the entire container/biochip combination without risk of moving the biochip.

Example 2: Test for mechanical resistance and  
for leaktightness of the attachment of the biochip to  
35 the container by adhesive bonding

A test rig was designed to validate the consumable elements bonded, by measuring the mechanical resistance and the leaktightness. In this test rig, the consumable elements are trapped between two plates

which form a cavity on either side of the biochip 2. The measurement is taken according to the differential pressure principle, which ensures good reliability of measurement. The measuring cavity is temperature controlled. The test rig is represented diagrammatically on figure 13.

After having introduced a buffer (25 mM sodium carbonate, pH 10, sold by the company Radiometer Analytical Villeurbanne, France, under the reference S11M007) onto one of the faces of the biochip, the test consists in exposing the device to a pressure of 900 mbar and to a temperature of 80°C for cycles of 30 minutes. The lack of variation on the two manometers 31 and 33 is a first indication of the resistance and of the leaktightness of the attachment means 5. The gaseous circuit comprises an inlet valve 32 and an outlet valve 34. A second visual control may be carried out by opening the test rig in order to verify that there is no liquid on the other face of the biochip.

The biochip 2 has a support 9 in the form of a glass square 5.37 mm ± 0.18 in size and 0.7 mm thick.

The window of the container has a square cross section 5.717 mm ± 0.05 or 5.577 mm ± 0.05 in size. This container is made of black polystyrene.

The adhesive used is the Dymax adhesive 1-20-280 or Loctite 3104 adhesive.

The conditions chosen are representative of extreme conditions for reactions between ligands and analytes since, for example, in the immunoassays field, the reaction temperature is often close to 37°C. In the nucleic acids domain, the temperature may vary between room temperature and 95°C, but the 95°C temperatures are denaturing temperatures which are required for short periods of time, of the order of a few minutes. Hybridization reactions generally take place between 30 and 60°C.

Table I below summarizes the results obtained.

Table I

Adhesive (5)	Window (81)	Number of tests (reproduc- bility)	Visual control after 30 minutes	Time during which the pressure does not vary
Dymax 1-20-280	5.717 mm	4	Positive	>230 minutes
Dymax 1-20-280	5.577 mm	2	Positive	>230 minutes
Loctite 3104	5.717 mm	2	Positive	>230 minutes
Loctite 3104	5.577 mm	4	Positive	>230 minutes

Independent tests are carried out in each scenario in order to verify the reproducibility of the results.

The tests carried out with a buffer at pH 6.0 (100 mM potassium phosphate, pH 6.0) produce results similar in terms of resistance.

The tests carried out with temperatures of 60°C increase the resistance times.

In all cases, the mechanical resistance and the leaktightness resistance are greater than 230 minutes, which indicates that the attachment means according to the invention is completely compatible with the reaction times commonly used in reactions between ligands and analytes.

The set of tests carried out demonstrates that the attachments means according to the invention can be automated, from the point of view of both the quality of the product and the conditions for producing a reliable automatic machine.

CLAIMS

1. A device (1) for analyzing at least one analyte, comprising, firstly, a biochip (2) comprising a support (9), for example a polyhedral support, comprising an active face (3) comprising an active surface (31), onto which are distributed and attached a plurality of ligands (4) used for the analysis, at least one face (6) opposite the active face (3), and a transverse peripheral strip (7) connecting the active (3) and opposite (6) faces, comprising, for example, several sides (71, 74), and, secondly, a container (8), and also an attachment means (5) placed on both sides of the active face (3) of the biochip (2), and connecting, on one side, the transverse strip (7) of the biochip, virtually excluding any other part, face or surface of said biochip (2) and, on the other side, the container (8), virtually completely exposing the peripheral zone (32) of the active face (3) of the biochip (2), the container (8) and the biochip (2) delimiting a reaction compartment (10), characterized in that the biochip (2) is in contact with the container (8) only via the attachment means (5), placed between, on one side, the transverse strip (7) of the biochip and, on the other side, the container (8); cf. figure 2 for example.
2. A device (1) for analyzing at least one analyte, comprising, firstly, a biochip (2) comprising a support (9), for example a polyhedral support, comprising an active face (3) comprising an active surface (31), onto which are distributed and attached a plurality of ligands (4) used for the analysis, at least one face (6) opposite the active face (3), and a transverse peripheral strip (7) connecting the active (3) and opposite (6) faces, comprising, for example, several sides (71, 74), and, secondly, a container (8) which has a window (81), through which said biochip is

attached via an attachment means (5) placed on both sides of the active face (3) of the biochip (2), the container (8) and the biochip (2) delimiting a reaction compartment (10), characterized in that the attachment means (5) of the biochip (2) connects, on one side, the transverse strip (7) of the biochip, virtually excluding any other part, including face or surface, of said biochip, virtually completely exposing the peripheral zone (32) of the active face (3) of said biochip and, on the other side, the frame of the window (81) of the container (8).

3. The device as claimed in claim 1, characterized in that the frame of the window (81) has an edge parallel to the transverse strip (7) of the biochip.

4. The analytical device as claimed in claim 1 or 2, characterized in that the attachment means completely exposes the active face (3).

5. The analytical device as claimed in claim 4, characterized in that the active surface (31) merges with the surface of the active face (3).

6. The analytical device as claimed in claim 1 or 2, characterized in that the attachment means (5) is an adhesive.

7. The analytical device as claimed in claim 2, characterized in that the container (8) has a window (81) with a transverse profile substantially identical to that of the support (9) of the biochip (2).

8. The analytical device as claimed in claim 2, characterized in that the window (81) of the container (8) is equipped with a means which allows a surplus of adhesive to be stored without it overflowing onto the peripheral zone (32) of the biochip (2).

9. The device as claimed in claim 8, characterized in that the means for storing a surplus of adhesive consists of a beveled shape (14) at the level of the window (81) of the container.

10. The analytical device as claimed in any one of claims 7 to 9, characterized in that the interstice between the border of the window (81) and the

transverse strip (7) of the biochip is between 2 mm and 0.05 mm, advantageously between 0.5 mm and 0.05 mm, and preferentially between 0.2 mm and 0.1 mm.

11. The analytical device as claimed in any one of 5 claims 1 to 10, characterized in that the attachment means extends along the entire transverse strip (7) of the biochip.

12. The analytical device as claimed in any one of claims 1 to 11, characterized in that the attachment 10 means (5) connects two opposite zones of the transverse strip (7), to the container (8).

13. The analytical device as claimed in claim 6, characterized in that the adhesive comprises a component which can be cured by ultraviolet radiation.

15. 14. The analytical device as claimed in any one of claims 1 to 13, characterized in that the support (9) of the biochip (2) is a parallelepiped, the active (3) and opposite (6) faces of which are each rectangular or square.

20. 15. The analytical device as claimed in any one of claims 1 to 14, characterized in that the reaction compartment (10) is arranged so as to bring a liquid medium, subjected to the analysis, and the active surface (31) of the biochip into contact.

25. 16. The analytical device as claimed in claim 15, characterized in that the attachment means (5) ensures that the reaction compartment (10) is leaktight with respect to the outside.

30. 17. The analytical device as claimed in any one of claims 1 to 16, characterized in that the active surface (31) of the biochip has a surface area of less than 100 mm<sup>2</sup>, advantageously less than 65 mm<sup>2</sup>, and preferentially less than 30 mm<sup>2</sup>.

35. 18. The analytical device as claimed in any one of claims 1 to 16, characterized in that the active surface (31) of the biochip represents at least 75% of the surface area of the active face (3).

19. The analytical device as claimed in any one of claims 1 to 18, characterized in that the ligands are nucleic acids.

20. The analytical device as claimed in claim 8, 5 characterized in that the means for storing a surplus of adhesive consists of a concavity present on all or part of the surround of the window (81) of the container (8), such as a groove or a channel.

21. The analytical device as claimed in any one of 10 claims 1 to 20, characterized in that the attachment means (5) comprises means which are flexible (12) at the level of the window (81) of the container (8), and exert a pressure on the transverse strip (7) of the biochip (2) so as to facilitate the positioning and/or 15 the maintaining in position of said biochip.

22. The analytical device as claimed in claim 21, characterized in that the flexible means (12) consist of two interdependent components, namely an intermediate component inclined relative to the 20 opposite face (6) of the biochip, and an end component substantially perpendicular to said opposite face, said end component exerting a pressure on the transverse strip (7) of the biochip.

23. The analytical device as claimed in claim 21, 25 characterized in that the flexible means (12) comprise claws, the cross section of which is substantially triangular.

24. A process for attaching a biochip to a container, for producing an analytical device as 30 claimed in any one of claims 1 to 23, characterized in that the biochip (2) is maintained opposite the container (8), in that a liquid adhesive seal is distributed between the transverse strip (7) of the biochip and the container (8), and in that the adhesive 35 (5) is cured by ultraviolet radiation.

25. The attachment process as claimed in claim 24, characterized in that the biochip (2) is positioned relative to the container (8) so as to place the


transverse strip (7) of the biochip opposite the frame of the window (81) of the container (8).

26. The attachment process as claimed in claim 25, characterized in that the biochip (2) and/or the 5 container (8) is (are) maintained on the positioning means by applying a vacuum.

27. The attachment process as claimed in any one of claims 24 to 26, characterized in that ultraviolet radiation is applied to the adhesive seal on at least 10 one of the faces of the analytical device.

28. The attachment process as claimed in any one of claims 24 to 27, characterized in that a mask is positioned between the biochip and the ultraviolet radiation in order to protect the ligands in the active 15 surface (31).

FIG 1



2 / 4

FIG 2




FIG 5




FIG 3A




FIG 3B




FIG 4




FIG 6





FIG 7



3 / 4

FIG8




FIG9





FIG10



4 / 4

FIG 11




FIG 12





FIG 13



**DECLARATION AND POWER OF ATTORNEY  
UNDER 35 USC §371(c)(4) FOR  
PCT APPLICATION FOR UNITED STATES PATENT**

As a below named inventor, I hereby declare that:  
my residence, post office address and citizenship are as stated below under my name;

I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought, namely the invention entitled: ANALYSING DEVICE WITH BIOCHIP

described and claimed in international application number PCT/FR00/02079 filed July 19, 2000.

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

Under Title 35, U.S. Code §119, the priority benefits of the following foreign application(s) filed by me or my legal representatives or assigns within one year prior to my international application are hereby claimed:

FR 99 09488 filed July 19, 1999

The following application(s) for patent or inventor's certificate on this invention were filed in countries foreign to the United States of America either (a) more than one year prior to my international application, or (b) before the filing date of the above-named foreign priority application(s):

I hereby appoint the following as my attorneys of record with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office:

*[Signature]*  
 James A. Oliff, Reg. No. 27,075; William P. Berridge, Reg. No. 30,024;  
 Kirk M. Hudson, Reg. No. 27,562; Thomas J. Pardini, Reg. No. 30,411;  
 Edward P. Walker, Reg. No. 31,450; Robert A. Miller, Reg. No. 32,771;  
 Mario A. Costantino, Reg. No. 33,565; Stephen J. Roe, Reg. No. 34,463;  
 Joel S. Armstrong, Reg. No. 36,430; Christopher W. Brown, Reg. No. 38,025;  
 Richard E. Rice, Reg. No. 31,560; and Paul Tsou, Reg. No. 37,956.

ALL CORRESPONDENCE IN CONNECTION WITH THIS APPLICATION SHOULD BE SENT TO OLIFF & BERRIDGE, PLC, P.O. BOX 19928, ALEXANDRIA, VIRGINIA 22320, TELEPHONE (703) 836-6400.

I hereby declare that I have reviewed and understand the contents of this Declaration, and that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	<b>Typewritten Full Name of Sole or First Inventor</b>	<i>[Signature]</i>	<u>Thomas</u>	Given Name	<u>GUERITAULT</u>	Family Name
2	<b>Inventor's Signature:</b>	<i>[Signature]</i>	<u>Thomas</u>	Middle Initial	<i>[Signature]</i>	<u>Gueritault</u>
3	<b>Date of Signature:</b>	<i>[Signature]</i>	<u>February</u>	<u>the 4<sup>th</sup></u>	Day	<u>2002</u>
	Month	Day	Year			
Residence:	<u>Renens</u>	City	State or Province	Switzerland	Country	<u>CH</u>
Citizenship:	<u>French</u>					
Post Office Address:	<u>Rue du Bugnon, 49</u>					
(Insert complete mailing address, including country)	<u>CH-1020 RENENS Switzerland</u>					

**Note to Inventor:** Please sign name on line 2 exactly as it appears in line 1 and insert the actual date of signing on line 3.

**IF THERE IS MORE THAN ONE INVENTOR USE PAGE 2 AND PLACE AN "X" HERE**   
(Discard this page in a sole inventor application)

DEPARTMENT OF PATENTS

1	Typewritten Full Name of Joint Inventor	Maxime	ODIET			
2	Inventor's Signature:	200	Given Name Maxime	Middle Initial	Family Name ODIET	
3	Date of Signature:	February	the 4 <sup>th</sup>	Month	Day	Year 2002
Residence:		Cormondreche	City	State or Province		Country Switzerland CH-X
Citizenship:		Switzerland				
Post Office Address: (Insert complete mailing address, including country)		Rue du Prieure, 1 CH-2036 CORMONDRECHE Switzerland				
1	Typewritten Full Name of Joint Inventor	300	Jean-Claude	PRELAZ		
2	Inventor's Signature:		Given Name Jean-Claude	Middle Initial	Family Name PRELAZ	
3	Date of Signature:	February	the 4 <sup>th</sup>	Month	Day	Year 2002
Residence:		Chez le Bart	City	State or Province		Country Switzerland CH-X
Citizenship:		Switzerland				
Post Office Address: (Insert complete mailing address, including country)		Payaz 5d CH-2025 CHEZ LE BART Switzerland				
1	Typewritten Full Name of Joint Inventor					
2	Inventor's Signature:		Given Name	Middle Initial	Family Name	
3	Date of Signature:					
Residence:			Month	Day	Year	
Citizenship:		City	State or Province		Country	
Post Office Address: (Insert complete mailing address, including country)						
1	Typewritten Full Name of Joint Inventor					
2	Inventor's Signature:		Given Name	Middle Initial	Family Name	
3	Date of Signature:					
Residence:			Month	Day	Year	
Citizenship:		City	State or Province		Country	
Post Office Address: (Insert complete mailing address, including country)						

Note to Inventor: Please sign name on line 2 exactly as it appears in line 1 and insert the actual date of signing on line 3.

This form may be executed only when attached to the first page of the Declaration and Power of Attorney of the application to which it pertains.